{"id":296392,"date":"2026-03-30T00:00:00","date_gmt":"2026-03-30T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algocv0025-2024-biopharma-venous-thromboembolism-current-treatment-treatment-algorithms-claims-data\/"},"modified":"2026-04-24T11:13:35","modified_gmt":"2026-04-24T11:13:35","slug":"algocv0025-2026-biopharma-venous-thromboembolism-current-treatment-treatment-algorithms-claims-data-analysis-venous","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algocv0025-2026-biopharma-venous-thromboembolism-current-treatment-treatment-algorithms-claims-data-analysis-venous\/","title":{"rendered":"Venous Thromboembolism &#8211; Current Treatment &#8211; Treatment Algorithms: Claims Data Analysis &#8211; Venous Thromboembolism (US)"},"content":{"rendered":"<p>Venous thromboembolism (<abbr title=\"venous thromboembolism\">VTE<\/abbr>) is the obstruction of a vein caused by a thrombus, described as deep vein thrombosis (<abbr title=\"deep vein thrombosis\">DVT<\/abbr>) or pulmonary embolism (<abbr title=\"pulmonary embolism\">PE<\/abbr>), depending on the vein affected. Anticoagulants are the standard of care for treating established <abbr title=\"venous thromboembolism\">VTE<\/abbr> and for prophylaxis of <abbr title=\"venous thromboembolism\">VTE<\/abbr>. Oral direct factor Xa inhibitors are the preferred class of anticoagulant, while vitamin K antagonists (<abbr title=\"vitamin K antagonist\">VKA<\/abbr>s), antiplatelets, and heparins are frequently prescribed drug classes. Severe cases of <abbr title=\"deep vein thrombosis\">DVT<\/abbr> or <abbr title=\"pulmonary embolism\">PE<\/abbr> may require thrombolytics to promote clot lysis before transitioning to anticoagulation. This analysis of claims data provides a quantitative picture of prescribing patterns for newly diagnosed and recently drug-treated <abbr title=\"venous thromboembolism\">VTE<\/abbr> patients in the United States.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What patient shares do key therapies and brands garner by line of therapy in newly diagnosed <abbr title=\"venous thromboembolism\">VTE<\/abbr> patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed <abbr title=\"venous thromboembolism\">VTE<\/abbr> patients?<\/li>\n<li>How have direct oral factor Xa inhibitors been integrated into the treatment algorithm, and what are their sources of business?<\/li>\n<li>What percentage of <abbr title=\"venous thromboembolism\">VTE<\/abbr> patients receive drug therapy within 730 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 730 days of diagnosis?<\/li>\n<li>What percentage of <abbr title=\"venous thromboembolism\">VTE<\/abbr> patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated patients?<\/li>\n<\/ul>\n<ul class=\"BulletListStyle1 SCXW74801641 BCX0 round-bullets\">\n<\/ul>\n<p><strong>Markets covered:<\/strong> United States<\/p>\n<p><strong>Key companies:<\/strong> Boehringer Ingelheim, Pfizer, Sanofi, Bristol Myers Squibb, Daiichi Sankyo, Johnson &#038; Johnson Innovative Medicine, Bayer, Genetech<\/p>\n<p><strong>Key drugs:<\/strong> Dabigatran etexilate mesylate, argatroban, dalteparin sodium, enoxaparin sodium, heparin sodium, fondaparinux sodium, apixaban, edoxaban, rivaroxaban, warfarin, alteplase<\/p>\n<p><strong>Product description<\/strong><\/p>\n<p>Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:<\/p>\n<ul class=\"BulletListStyle1 SCXW74801641 BCX0 round-bullets\">\n<li>Understand patient flow between lines of therapy.<\/li>\n<li>Evaluate your brand share against competitors.<\/li>\n<li>Accurately assess your source of business.<\/li>\n<li>Quantify opportunities at different stages of the treatment algorithm.<\/li>\n<\/ul>\n<p><strong>Product enhancement<\/strong><\/p>\n<p>Treatment Algorithms: Claims Data Analysis leverages Clarivate\u2019s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.<\/p>\n<p><strong>Key feature<\/strong><\/p>\n<p>Dashboard featuring interactive visuals, easy navigation, and expanded analyses<\/p>\n","protected":false},"template":"","class_list":["post-296392","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-cardiovascular","biopharma-therapy-areas-venous-thromboembolism","biopharma-product-current-treatment","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296392","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":10,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296392\/revisions"}],"predecessor-version":[{"id":577776,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296392\/revisions\/577776"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=296392"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}